These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

142 related articles for article (PubMed ID: 15160958)

  • 1. Enhanced cytotoxicity of rituximab following genetic and biochemical disruption of glycosylphosphatidylinositol anchored proteins.
    Nagajothi N; Matsui WH; Mukhina GL; Brodsky RA
    Leuk Lymphoma; 2004 Apr; 45(4):795-9. PubMed ID: 15160958
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Correction of the PNH defect by GPI-anchored protein transfer.
    Sloand EM; Maciejewski JP; Dunn D; Moss J; Brewer B; Kirby M; Young NS
    Blood; 1998 Dec; 92(11):4439-45. PubMed ID: 9834251
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Congenital Defects in the Expression of the Glycosylphosphatidylinositol-Anchored Complement Regulatory Proteins CD59 and Decay-Accelerating Factor.
    Kinoshita T
    Semin Hematol; 2018 Jul; 55(3):136-140. PubMed ID: 30032750
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Paroxysmal nocturnal hemoglobinuria from bench to bedside.
    Pu JJ; Brodsky RA
    Clin Transl Sci; 2011 Jun; 4(3):219-24. PubMed ID: 21707954
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Paroxysmal nocturnal haemoglobinuria.
    Hill A; DeZern AE; Kinoshita T; Brodsky RA
    Nat Rev Dis Primers; 2017 May; 3():17028. PubMed ID: 28516949
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Deficient surface expression of glycosylphosphatidylinositol-anchored proteins in B cell lines established from patients with paroxysmal nocturnal hemoglobinuria.
    Ueda E; Nishimura J; Kitani T; Nasu K; Kageyama T; Kim YU; Takeda J; Kinoshita T
    Int Immunol; 1992 Nov; 4(11):1263-71. PubMed ID: 1282030
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Transfer of glycosylphosphatidylinositol-anchored proteins to deficient cells after erythrocyte transfusion in paroxysmal nocturnal hemoglobinuria.
    Sloand EM; Mainwaring L; Keyvanfar K; Chen J; Maciejewski J; Klein HG; Young NS
    Blood; 2004 Dec; 104(12):3782-8. PubMed ID: 15304386
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Improved detection and characterization of paroxysmal nocturnal hemoglobinuria using fluorescent aerolysin.
    Brodsky RA; Mukhina GL; Li S; Nelson KL; Chiurazzi PL; Buckley JT; Borowitz MJ
    Am J Clin Pathol; 2000 Sep; 114(3):459-66. PubMed ID: 10989647
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Resistance of paroxysmal nocturnal hemoglobinuria cells to the glycosylphosphatidylinositol-binding toxin aerolysin.
    Brodsky RA; Mukhina GL; Nelson KL; Lawrence TS; Jones RJ; Buckley JT
    Blood; 1999 Mar; 93(5):1749-56. PubMed ID: 10029605
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Mechanisms by which the surface expression of the glycosyl-phosphatidylinositol-anchored complement regulatory proteins decay-accelerating factor (CD55) and CD59 is lost in human leukaemia cell lines.
    Hatanaka M; Seya T; Matsumoto M; Hara T; Nonaka M; Inoue N; Takeda J; Shimizu A
    Biochem J; 1996 Mar; 314 ( Pt 3)(Pt 3):969-76. PubMed ID: 8615796
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Paroxysmal nocturnal hemoglobinuria in children.
    van den Heuvel-Eibrink MM
    Paediatr Drugs; 2007; 9(1):11-6. PubMed ID: 17291133
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Correction of the PNH defect by GPI protein transfer: still an open question.
    Bütikofer P
    Blood; 2000 Mar; 95(5):1876-8. PubMed ID: 10744388
    [No Abstract]   [Full Text] [Related]  

  • 13. Biologic response of B lymphoma cells to anti-CD20 monoclonal antibody rituximab in vitro: CD55 and CD59 regulate complement-mediated cell lysis.
    Golay J; Zaffaroni L; Vaccari T; Lazzari M; Borleri GM; Bernasconi S; Tedesco F; Rambaldi A; Introna M
    Blood; 2000 Jun; 95(12):3900-8. PubMed ID: 10845926
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Glycosylphosphatidylinositol (GPI)-anchored membrane proteins in clinical pathophysiology of paroxysmal nocturnal hemoglobinuria (PNH).
    Shichishima T
    Fukushima J Med Sci; 1995 Jun; 41(1):1-13. PubMed ID: 8606038
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Expression of complement inhibitors CD46, CD55, and CD59 on tumor cells does not predict clinical outcome after rituximab treatment in follicular non-Hodgkin lymphoma.
    Weng WK; Levy R
    Blood; 2001 Sep; 98(5):1352-7. PubMed ID: 11520782
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Glycosyl phosphatidylinositol-linked blood group antigens and paroxysmal nocturnal hemoglobinuria.
    Telen MJ
    Transfus Clin Biol; 1995; 2(4):277-90. PubMed ID: 8542026
    [TBL] [Abstract][Full Text] [Related]  

  • 17. CD20 levels determine the in vitro susceptibility to rituximab and complement of B-cell chronic lymphocytic leukemia: further regulation by CD55 and CD59.
    Golay J; Lazzari M; Facchinetti V; Bernasconi S; Borleri G; Barbui T; Rambaldi A; Introna M
    Blood; 2001 Dec; 98(12):3383-9. PubMed ID: 11719378
    [TBL] [Abstract][Full Text] [Related]  

  • 18. [Paroxysmal nocturnal hemoglobinuria (PNH). Pathogenesis, diagnosis and treatment].
    Röth A; Dührsen U; Schrezenmeier H; Schubert J
    Dtsch Med Wochenschr; 2009 Feb; 134(9):404-9. PubMed ID: 19224425
    [TBL] [Abstract][Full Text] [Related]  

  • 19. The phenotype of a germline mutation in PIGA: the gene somatically mutated in paroxysmal nocturnal hemoglobinuria.
    Johnston JJ; Gropman AL; Sapp JC; Teer JK; Martin JM; Liu CF; Yuan X; Ye Z; Cheng L; Brodsky RA; Biesecker LG
    Am J Hum Genet; 2012 Feb; 90(2):295-300. PubMed ID: 22305531
    [TBL] [Abstract][Full Text] [Related]  

  • 20. A new aspect of the molecular pathogenesis of paroxysmal nocturnal hemoglobinuria.
    Shichishima T; Noji H
    Hematology; 2002 Aug; 7(4):211-27. PubMed ID: 14972783
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 8.